文献速递肿瘤 PET/CT核素与放射性配体治疗

氟昔洛韦PET/CT在伴肾上腺转移的去势抵抗性前列腺癌中的潜在陷阱

Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis.
PubMed 文献 · Clin Nucl Med · 2022-08-26

一例83岁去势抵抗性前列腺癌患者行18F-氟昔洛韦PET/CT,局部及区域淋巴结阴性,见多发氟昔洛韦高摄取骨转移,双侧肾上腺轻度摄取结节初判良性;10个月后随访PET/CT示双侧结节增大为肿块且氟昔洛韦摄取间隔性减低,疑肾上腺转移,CT引导活检证实前列腺癌转移且无肿瘤坏死。该假阴性病例凸显氟昔洛韦PET表征肾上腺病灶的诊断挑战。

要点

  • 氟昔洛韦PET/CT可漏诊前列腺癌肾上腺转移,双侧轻度摄取结节不应轻判良性。
  • 随访中肾上腺结节增大为肿块且摄取间隔性减低,活检证实为转移且无坏死。
  • 该假阴性病例提示氟昔洛韦PET表征肾上腺病灶存在诊断挑战。

核心结论

  • 该假阴性病例凸显氟昔洛韦PET在表征肾上腺病灶方面的诊断挑战。

研究设计与样本

  • 个案报告:一例83岁去势抵抗性前列腺癌患者行18F-氟昔洛韦PET/CT及10个月后随访PET/CT,并行CT引导活检。

主要发现

  • 首次18F-氟昔洛韦PET/CT对局部复发或区域淋巴结病变阴性,但见多发氟昔洛韦高摄取骨转移。
  • 首次检查见双侧肾上腺轻度摄取结节,当时考虑为良性。
  • 10个月后随访PET/CT(患者正在接受恩扎卢胺额外治疗)示双侧结节变为肿块病变,氟昔洛韦摄取间隔性减低。
  • 因快速生长怀疑肾上腺转移,CT引导活检证实为前列腺癌转移且无肿瘤坏死。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An 83-year-old man with castrate-resistant prostate cancer underwent an 18 F-fluciclovine PET/CT scan, which was negative for local disease recurrence or locoregional lymphadenopathy, but there were multiple fluciclovine-avid bone metastases. In addition, mildly avid bilateral adrenal nodules were thought to be benign. However, on follow-up PET/CT 10 months later, while on additional therapy with enzalutamide, the bilateral nodules became mass lesions with interval decreased fluciclovine avidity. Adrenal metastases were suspected given their rapid growth, with subsequent CT-guided biopsy revealing metastatic prostate cancer without tumor necrosis. This false-negative case highlights the diagnostic challenge of fluciclovine PET in characterizing adrenal lesions.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Qi J, Nguyen NC. Potential Pitfall of Fluciclovine PET/CT in Castrate-Resistant Prostate Cancer With Adrenal Metastasis. Clin Nucl Med. 2022. PMID: 36026595. doi:10.1097/RLU.0000000000004373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。